{
    "2021-02-26": [
        [
            {
                "time": "",
                "orginal_text": "基因测序一周风云榜：药明康德市值蒸发超400亿元，达安基因“万绿丛中一点红” 连续下跌",
                "features": {
                    "keywords": [
                        "药明康德",
                        "市值蒸发",
                        "连续下跌",
                        "达安基因"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "基因测序"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "制药行业一周风云榜：CRO企业AH两市暴跌，药明康德市值一周缩水700亿 连续下跌",
                "features": {
                    "keywords": [
                        "CRO",
                        "AH两市",
                        "暴跌",
                        "药明康德",
                        "市值缩水"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "昭衍新药港股上市，第四家“A+H”CRO企业诞生！",
                "features": {
                    "keywords": [
                        "昭衍新药",
                        "港股上市",
                        "A+H",
                        "CRO"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "因可转换债券获转换 药明康德(02359)折让53.00%发行143.42万股H股",
                "features": {
                    "keywords": [
                        "可转换债券",
                        "药明康德",
                        "折让",
                        "H股"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "行业专业分工明确，百洋将成继“药明康德”后又一专业第三方平台",
                "features": {
                    "keywords": [
                        "百洋",
                        "药明康德",
                        "第三方平台"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药",
                        "医疗平台"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "【异动股】药明康德(02359-HK)跌3.12%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "异动股",
                        "下跌"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "医药行业2020年报及2021年一季报业绩前瞻：2020分化巨大 21Q1恢复良好",
                "features": {
                    "keywords": [
                        "医药行业",
                        "2020年报",
                        "2021一季报",
                        "业绩前瞻",
                        "分化",
                        "恢复"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "大摩：上调药明康德目标价至178港元，评级增持",
                "features": {
                    "keywords": [
                        "大摩",
                        "药明康德",
                        "目标价",
                        "上调",
                        "增持"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "新冠疗法临床试验中只有5%能够给出指导性结果？FDA代理局长联名发文",
                "features": {
                    "keywords": [
                        "新冠疗法",
                        "临床试验",
                        "FDA",
                        "指导性结果"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "新冠治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}